3 ms·
It really depends on disease prevalence, technological capability and urgency. For example during ebola epidemic RVSV-ZEBOV vaccine was administered to infecte
by nojokes 5y ago
It really depends on disease prevalence, technological capability and urgency. For example during ebola epidemic RVSV-ZEBOV vaccine was administered to infected people prior any previous human testing. H1N1 vaccine was developed in number of months (3rd phase trial size was 2200 persons) but sufficient and timely mass production failed.